Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1964 1
1973 1
1975 1
1977 1
1978 1
1983 1
1988 1
1990 1
1992 3
1994 4
1995 8
1996 2
1997 5
1998 3
1999 4
2000 6
2001 6
2002 3
2003 7
2004 12
2005 9
2006 17
2007 14
2008 13
2009 12
2010 16
2011 17
2012 26
2013 26
2014 25
2015 34
2016 30
2017 37
2018 34
2019 24
2020 39
2021 40
2022 47
2023 39
2024 36
2025 46

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

577 results

Results by year

Filters applied: . Clear all
Page 1
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Levis MJ, et al. Among authors: papadopoulos eb. J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12. J Clin Oncol. 2024. PMID: 38471061 Free PMC article. Clinical Trial.
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Oshima MU, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly LS, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Mendizabal A, Devine SM, Horowitz MM, Chen YB. Levis MJ, et al. Among authors: papadopoulos eb. Blood. 2025 May 8;145(19):2138-2148. doi: 10.1182/blood.2024025154. Blood. 2025. PMID: 39775763 Free article. Clinical Trial.
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.
Zhang H, Christensen CL, Dries R, Oser MG, Deng J, Diskin B, Li F, Pan Y, Zhang X, Yin Y, Papadopoulos E, Pyon V, Thakurdin C, Kwiatkowski N, Jani K, Rabin AR, Castro DM, Chen T, Silver H, Huang Q, Bulatovic M, Dowling CM, Sundberg B, Leggett A, Ranieri M, Han H, Li S, Yang A, Labbe KE, Almonte C, Sviderskiy VO, Quinn M, Donaghue J, Wang ES, Zhang T, He Z, Velcheti V, Hammerman PS, Freeman GJ, Bonneau R, Kaelin WG Jr, Sutherland KD, Kersbergen A, Aguirre AJ, Yuan GC, Rothenberg E, Miller G, Gray NS, Wong KK. Zhang H, et al. Among authors: papadopoulos e. Cancer Cell. 2020 Jan 13;37(1):37-54.e9. doi: 10.1016/j.ccell.2019.11.003. Epub 2019 Dec 26. Cancer Cell. 2020. PMID: 31883968 Free PMC article.
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. Cardoso F, et al. Among authors: papadopoulos e. Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192. Ann Oncol. 2018. PMID: 30032243 Free PMC article. No abstract available.
Preface.
Papadopoulos E. Papadopoulos E. Vet Parasitol. 2015 Sep 30;213(1-2):1. doi: 10.1016/j.vetpar.2015.10.010. Vet Parasitol. 2015. PMID: 26522625 No abstract available.
Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC.
Zhang H, Nabel CS, Li D, O'Connor RÍ, Crosby CR, Chang SM, Hao Y, Stanley R, Sahu S, Levin DS, Chen T, Tang S, Huang HY, Meynardie M, Stephens J, Sherman F, Chafitz A, Costelloe N, Rodrigues DA, Fogarty H, Kiernan MG, Cronin F, Papadopoulos E, Ploszaj M, Weerasekara V, Deng J, Kiely P, Bardeesy N, Vander Heiden MG, Chonghaile TN, Dowling CM, Wong KK. Zhang H, et al. Among authors: papadopoulos e. J Thorac Oncol. 2023 Jul;18(7):882-895. doi: 10.1016/j.jtho.2023.03.014. Epub 2023 Mar 22. J Thorac Oncol. 2023. PMID: 36958689 Free PMC article.
Editorial: Robotic Manipulation and Capture in Space.
Papadopoulos E, Aghili F, Ma O, Lampariello R. Papadopoulos E, et al. Front Robot AI. 2022 Feb 2;9:849288. doi: 10.3389/frobt.2022.849288. eCollection 2022. Front Robot AI. 2022. PMID: 35187096 Free PMC article. No abstract available.
Patient-Reported Outcomes in Glomerular Disease.
Selewski DT, Thompson A, Kovacs S, Papadopoulos EJ, Carlozzi NE, Trachtman H, Troost JP, Merkel PA, Gipson DS. Selewski DT, et al. Among authors: papadopoulos ej. Clin J Am Soc Nephrol. 2017 Jan 6;12(1):140-148. doi: 10.2215/CJN.13231215. Epub 2016 Jun 3. Clin J Am Soc Nephrol. 2017. PMID: 27259977 Free PMC article. Review.
Feline leishmaniosis in the Mediterranean Basin: a multicenter study.
Carbonara M, Iatta R, Miró G, Montoya A, Benelli G, Mendoza-Roldan JA, Papadopoulos E, Lima C, Bouhsira E, Nachum-Biala Y, Decaro N, Schunack B, Baneth G, Otranto D. Carbonara M, et al. Among authors: papadopoulos e. Parasit Vectors. 2024 Aug 19;17(1):346. doi: 10.1186/s13071-024-06419-x. Parasit Vectors. 2024. PMID: 39160611 Free PMC article.
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.
Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Oshima MU, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly LS, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson K, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal A, Devine SM, Horowitz MM, Chen YB. Levis MJ, et al. Among authors: papadopoulos eb. Blood Adv. 2025 Oct 28;9(20):5123-5133. doi: 10.1182/bloodadvances.2025016306. Blood Adv. 2025. PMID: 40590852 Free PMC article. Clinical Trial.
577 results